Amporin Pharmaceuticals

1. Executive Summary (Confidence: High)

Amporin Pharmaceuticals is a high-potential entrant in the longevity and neurodegeneration sectors, founded in April 2024 in Basel, Switzerland. The organization is pioneering a breakthrough scientific approach that shifts the therapeutic focus away from insoluble amyloid fibrils—which have largely failed in clinical trials—toward toxic soluble misfolded protein oligomers. These oligomers aggregate into "amyloid pores" that puncture holes in cell membranes, causing a lethal influx of calcium and subsequent degeneration. Amporin's leadership team, consisting of Big Pharma veterans from Roche, Novartis, and various biotechs, is developing a pipeline of small molecule inhibitors categorized as Amporbans, Amporins, and Amportacs. Having already secured seed validation through the Venture Kick program, the organization is currently building a robust in vitro data package to support its first clinical targets in Parkinson's and ALS.